Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo

The recruitment status of this study is unknown because the information has not been verified recently.

Verified November 2009 by Shahid Beheshti Medical University.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Shahid Beheshti Medical University

ClinicalTrials.gov Identifier:

NCT01330524

First received: March 8, 2011

Last updated: April 5, 2011

Last verified: November 2009

History of Changes

Tracking Information
First Received Date ^ICMJE	March 8, 2011
Last Updated Date	April 5, 2011
Start Date ^ICMJE	January 2010
Estimated Primary Completion Date	November 2010 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: April 5, 2011)	Changes of Best corrected visual acuity(BCVA) [ Time Frame: 6 month ] [ Designated as safety issue: Yes ] outcome method of measurement: Snellen chart
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	Complete list of historical versions of study NCT01330524 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE (submitted: April 5, 2011)	Changes of Visual Field [ Time Frame: 6 month ] [ Designated as safety issue: Yes ] Automated perimeter
Original Secondary Outcome Measures ^ICMJE	Same as current
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo
Official Title ^ICMJE	Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy
Brief Summary	In this study 16 Patients diagnosed with Nonarteritic Anterior Ischemic Optic Neuropathy(NSION) who had a sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn in less than 30 days without exclusion criteria are randomly divided in two groups 1) control 2) case. In case group Avastin and Triamcinolone will be injected trough vitreal and placebo will be injected in control group. BCVA and Visual field will be then measured in these two groups.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 1 Phase 2
Study Design ^ICMJE	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Investigator, Outcomes Assessor) Primary Purpose: Treatment
Condition ^ICMJE	Acute Nonarteritic Anterior Ischemic Optic Neuropathy
Intervention ^ICMJE	Drug: Avastin and Triamcinolone 1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal Other: placebo 2mg placebo
Study Arm (s)	Active Comparator: Avastin and Triamcinolone Intervention: Drug: Avastin and Triamcinolone Placebo Comparator: Placebo Intervention: Other: placebo
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Recruiting
Estimated Enrollment ^ICMJE	16
Estimated Completion Date	November 2011
Estimated Primary Completion Date	November 2010 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion criteria: Sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn (<30 days) Exclusion criteria: Any eye disease except NAION(Nonarteritic Anterior Ischemic Optic Neuropathy) Neurologic defect Abnormal ESR, CRP, any history of retina or vitreal surgery Severe corneal opacity which makes retina examination impossible
Gender	Both
Ages	Not Provided
Accepts Healthy Volunteers	No
Contacts ^ICMJE
Listed Location Countries ^ICMJE	Iran, Islamic Republic of
Removed Location Countries

Administrative Information
NCT Number ^ICMJE	NCT01330524
Other Study ID Numbers ^ICMJE	8749
Has Data Monitoring Committee	Not Provided
Responsible Party	morteza entezari, Ophthalmic Research center
Study Sponsor ^ICMJE	Shahid Beheshti Medical University
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Shahid Beheshti Medical University
Verification Date	November 2009
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top